5034-68-4

Usage

Uses

As the specifics on L-Tyrosinol are not readily available, it is difficult to list its uses based on the provided materials. However, given its relation to L-Tyrosine, it can be inferred that L-Tyrosinol may have potential applications in areas where L-Tyrosine is utilized. These applications may include:
Used in Pharmaceutical Industry:
L-Tyrosinol could potentially be used as a precursor for the synthesis of neurotransmitters, similar to L-Tyrosine, for applications in the treatment of neurological disorders or cognitive enhancement.
Used in Nutritional Supplements:
L-Tyrosinol might be used as a dietary supplement to support the production of neurotransmitters, although more research is needed to confirm its effectiveness and safety.

InChI:InChI=1/C9H13NO2/c10-8(6-11)5-7-1-3-9(12)4-2-7/h1-4,8,11-12H,5-6,10H2

Upstream product

• 1080-06-4 L-Tyr-OMe 
• 949-67-7 L-tyrosine ethyl ester 
• 4089-07-0 L-tyrosine ethyl ester monohydrochloride 
• 60-18-4 L-tyrosine 
• 40829-66-1 (S)-2-(benzyloxycarbonylamino)-3-(4-hydroxyphenyl)-1-propanol 
• 402832-83-1 isovaleryl-L-tyrosyl-L-valyl-L-tyrosinol 
• 402832-86-4 n-butyryl-L-tyrosyl-L-leucyl-L-tyrosynol 
• 13512-31-7 N-(benzyloxycarbonyl)-L-tyrosine methyl ester 
• 3417-91-2 L-tyrosine methyl ester HCl 
• 1164-16-5 Z-L-Tyr-OH 
• 87745-27-5 (S)-tyrosinol hydrochloride 
• 83345-46-4 N-(tert-butyloxycarbonyl)-L-tyrosinol 
• 402832-91-1 [1-benzyloxymethyl-2-(4-benzyloxy-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 402832-92-2 {(S)-1-[(S)-1-Benzyloxymethyl-2-(4-benzyloxy-phenyl)-ethylcarbamoyl]-2-methyl-propyl}-carbamic acid tert-butyl ester 

Downstream Products

• 108842-49-5 N,O,O-triacetyl-S-tyrosinol 
• 126257-06-5 (S)-N-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)propionamide 
• 885021-83-0 (Z)-18-Bromo-octadec-9-enoic acid [(S)-1-hydroxymethyl-2-(4-hydroxy-phenyl)-ethyl]-amide 
• 863544-74-5 (Z)-N-[(1S)-2-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-1-[[4-[[(1,1-dimethylethyl)diphenylsilyl]oxy]phenyl]methyl]ethyl]-12-hydroxy-9-dodecenamide 
• 885022-93-5 (Z)-N-[(1S)-2-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-1-[[4-[[(1,1-dimethylethyl)diphenylsilyl]oxy]phenyl]methyl]ethyl]-12-(benzoyloxy)-9-dodecenamide 
• 863544-73-4 (Z)-N-[(1S)-2-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-1-[[4-[[(1,1-dimethylethyl)diphenylsilyl]oxy]phenyl]methyl]ethyl]-12-[(tetrahydro-2H-pyran-2-yl)oxy]-9-dodecenamide 
• 928122-38-7 2-azido-5-iodo-benzoic acid 11-{1-(tert-butyl-diphenyl-silanyloxymethyl)-2-[4-(tert-butyl-diphenyl-silanyloxy)-phenyl]-ethylcarbamoyl}-undec-3-enyl ester 
• 1407180-48-6 (4S)-2-isopropyl-4-(4-hydroxyphenylmethyl)-1,3-oxazolidine 
• 898818-83-2 4-{(2S)-3-hydroxy-2-[(3-nitroquinolin-4-yl)amino]propyl}phenol 
• 20649-40-5 (E)-4-(3-hydroxyprop-1-enyl)phenol 
• 1201814-12-1 (S)-di-tert-butyl 2,2'-(1-(4-(2-tert-butoxy-2-oxoethoxy)phenyl)-3-hydroxypropan-2-ylazanediyl) diacetate 
• 1312584-16-9 tert-butyl (1S,2S)-1-(5-(((S)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-ylamino)methyl)oxazol-2-yl)-2-methylbutylcarbamate 
• 1423401-50-6 (-)-4-[4-{2-hydroxy-1-(4-hydroxybenzyl)ethylaminomethyl}benzyloxy]-3,5-bis(hydroxymethyl)phenylacetylene 
• 1068142-18-6 (S)-N-{1-azido-3-[4-(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-heptadecafluoroundecyloxy)phenyl]prop-2-yl} methanesulfonamide 

Relevant academic research and scientific papers

Study of alkaloids of the Siberian and Altai flora 9. Synthesis of amino derivatives of elatidine

New secondary-tertiary diamines were prepared from elatidal imines with primary amino alcohols, derivatives of natural amino acids of the S-series. N-Methylation of the diamines yielded bi-tertiary diamines unable to undergo quaternization with MeI due to

N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation

Compounds for use in the treatment or prophylaxis of pain, including acute and chronic pain (e.g., nociceptive pain, neuropathic pain, headaches, migraine), represented by general formula (I) in which: the dotted line represents a single or a double bond; and R5 and R5′ are independently —H, —OH or —OR6, where R6 is a linear or branched C1-C4 alkyl; X is -0-, —CH2O—, —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; Z is —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; m is an integer of O or 1; and n is an integer of 0-50. The compounds of the invention are also effective for reducing inflammation and may be used alone or in combination with other analgesics.

Two modes of asymmetric polymerization of phenylacetylenes having an L -amino alcohol residue and two hydroxy groups

Four novel chiral phenylacetylenes having an L-amino alcohol residue and two hydroxymethyl groups were synthesized and polymerized by an achiral catalyst ((nbd)Rh+[η6-(C6H5)B -(C6H5)3]) or a chiral catalytic system ([Rh(nbd)Cl]2/(S)- or (R)-phenylethylamine ((S)- or (R)-PEA)). The two resulting polymers having an L-valinol or L-phenylalaninol residue showed Cotton effects at wavelengths around 430 nm. This observation indicated that they had an excess of one-handed helical backbones. Positive and negative Cotton effects were observed only for the polymers having an L-valinol residue produced by using (R)- and (S)-PEA as a cocatalyst, respectively, although the monomer had the same chirality. Even when the achiral catalyst was used, the two resulting polymers having an L-valinol or L-phenylalaninol residue showed Cotton effects despite the long distance between the chiral groups and the main chain. We have found the first example of a new type of chiral monomer, that is, a chiral phenylacetylene monomer having an L-amino alcohol residue and two hydroxy groups that was suitable for both modes of asymmetric polymerization, that is, the helix-sense-selective polymerization (HSSP) with the chiral catalytic system and the asymmetric-induced polymerization (AIP) with the achiral catalyst. The other two monomers having L-alaninol and L-tyrosinol were found to be unsuitable to neither HSSP nor AIP because of their polymers' low solubility.

Efficient synthesis of functionalized aziridinium salts

(Chemical Equation Presented) Various aziridinium salts were efficiently prepared from bromination of a series of backbone substituted N,N-bisubstituted β-amino alcohols and isolated via flash column chromatography. The effect of C-substitution, N-substitution, solvent, leaving group, and counter-anions on formation of the isolable aziridinium salts was investigated. 2009 American Chemical Society.

Use of Syk Tyrosine Kinase Inhibitors for the Treatment of Cell Proliferative Disorders

The invention relates to polyalkylene glycol compounds and their use in treating cell proliferative disorders, more specifically Syk tyrosine kinase-mediated disorders.

Synthesis and biological activity of new potential agonists for the human adenosine A2A receptor

New adenosine derivatives have been synthesized and tested as putative agonists of adenosine receptors. Compounds 2-6 derive from the introduction of several types of substituents (electron donating, electron withdrawing, and halogens) in the para-position of the phenyl ring of the parent compound 1, and compound 7 lacks the hydroxyl group of amino alcohol 1. In radioligand binding assays using recombinant human A1, A2A, A2B, and A3 receptors, all compounds showed very low or negligible affinity for A1 and A2B receptors but compounds 3, 5, and 7 displayed a remarkably potent affinity for the A2A receptor with Ki values of 1-5 nM. Bromo derivative 3 displayed a selectivity A1/A2A = 62 and A3/A2A = 16 whereas the presence of a hydroxyl group (compound 5) improved the selectivity of A 1/A2A and A3/A2A to 120- and 28-fold, respectively. When the methoxy derivative 4 lacks the hydroxyl group on the side chain (compound 7), the binding affinity for A2A is increased to 1 nM, improving selectivity ratios to 356- and 100-fold against A1 and A3, respectively. In Chinese hamster ovary cells transfected with human A2A and A2B receptors, most compounds showed a remarkable activity for the A2A receptor, except chloro derivative 2, with EC50 values ranging from 1.4 to 8.8 nM. The compounds behaved as good A2A agonists, and all were more selective than 5′-(N-ethylcarboxamino)adenosine (NECA), with A2B/A 2A ratios of cAMP accumulation ranging from 48 for compound 2 to 666 for compound 7 while the corresponding A2B/A2A ratio for NECA was only 9. Compounds 1, 3, 5, and 7 also displayed higher selectivities than NECA up to 100-fold in isolated aortas of rat and guinea pig. In guinea pig tracheal rings precontracted by carbachol, compounds 2 and 4 were more potent than adenosine (100-fold) and NECA (10-fold), whereas compounds I and 7 displayed similar effects to NECA. Pretreatment of the tracheal rings with A2, A2A, and A2B receptor antagonists 3,7-dimethyl-L-propargylxanthine, 8-(3-chlorostyryl)caffeine, and alloxazine produced a marked inhibition of the tracheal relaxations induced by compounds 1, 2, and 4, but none of the compounds showed selectivity toward any of the adenosine receptors.

Syntheses of amino alcohols and chiral C2-symmetric bisoxazolines derived from O-alkylated R-4-hydroxyphenylglycine and S-tyrosine

Chiral C2-symmetric bisoxazolines 1b-f and 2b,c, derived from 4′-O-alkylated R-4-hydroxyphenylglycine or S-tyrosine, were prepared. As intermediates, a series of chiral amino alcohols possessing substituted phenolic groups was prepared and fully characterized.

Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents

This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.

Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2 II. Structure determination and synthesis

The structures of tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2, were determined by analysis of various NMR experiments. The 1H and 13C NMR of tyropeptins were complicated due to the presence of an aldehyde group. Therefore, tyropeptins were converted to their alcohols by sodium borohydride. These alcohol derivatives gave assignable NMR spectra. The stereochemistry of tyropeptins were determined by analysis of acid hydrolysis products from tyropeptins, and further confirmed by the total synthesis. The structures of tyropeptins A and B were found to be isovaleryl-L-tyrosyl-L-valyl-DL-tyrosinal and n-butyryl-L-tyrosyl-L-leucyl-DL-tyrosinal, respectively.

New 1,4-anthracene-9,10-dione derivatives as potential anticancer agents

The amino-substituted anthracene-9,10-dione (9,10-anthraquinone) derivatives represent one of the most important classes of potential anticancer agents. To better understand the basic rules governing DNA sequence specificity, we have recently synthesized a new class of d- and l- aminoacyl-anthraquinone derivatives. We have tested these new compounds as cytotoxic agents, and we have correlated their activity with the configuration of the chiral aminoacyl moiety. Molecular modeling studies have been performed to compare the test drugs in terms of steric overlapping. (C) 2000 Elsevier Science S.A.